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The covalently bound polymers of peptidoglycan and group-specific polysac-
charide (PG-APS) were isolated from the cell walls of group A streptococci.
Arthritis was induced in rats with a single intraperitoneal injection of an aqueous
suspension of PG-APS fragments derived by sonication. The joint lesions induced
with this polydisperse suspension followed a bimodal pattern consisting of an
acute phase, which reached a peak 5 days after injection and then receded,
followed by a chronic, remittent, erosive arthritis lasting several months. The
relative severities of the acute and chronic phases could be manipulated by
selection of the size of PG-APS fragments. The fragments of PG-APS obtained by
sonic treatment were resolved on the basis of size into three major populations by
sucrose gradient or differential centrifugation. Based upon light scattering and gel
filtration, the average molecular weight of the largest family of fragments was
estimated to be about 500 x 106, the intermediate fragments were 50 x 106
daltons, and the predominant size in the smallest population was 5.3 x 106
daltons. The larger fragments induced negligible acute inflammation, but chronic
disease became apparent 5 to 9 weeks after injection. The smallest fragments
induced the most severe acute inflammation, with relatively little late, chronic
joint disease. The particles of intermediate size induced moderate acute inflamma-
tion and the most severe chronic, erosive joint lesions. A single injection of
fragments of the isolated peptidoglycan moiety of the PG-APS induced only a
moderate acute inflammation ofjoints, with no apparent capacity to maintain the
injury and induce chronic disease.
Earlier reports have described the histologi-
cal, radiological, and immunological features of
the chronic, erosive synovitis induced in rats or
guinea pigs with cell wall fragments isolated
from group A streptococci (4-7). This experi-
mental arthritis is produced with a single intra-
peritoneal (i.p.) injection of an aqueous suspen-
sion of cell wall fragments and has a bimodal
pattern in the rat. The first phase is an acute
inflammation ofjoints, which reaches a peak at 3
to 5 days after injection and then recedes. This is
followed by a chronic, remittent phase, which
first appears at about 3 weeks and is associated
with destruction of cartilage. The disease pro-
gresses over a period of several months to
ankylosis of the joints.
The purified cell wall preparation consists of
covalently bound polymers of peptidoglycan
(PG) and group-specific polysaccharide (APS).
t Present address: Department of Microbiology and Immu-
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One of our objectives is to define the minimal
structural unit of the PG-APS polymer which is
required to induce the experimental disease.
Previous studies have shown that intact, heat-
killed group A streptococcal cells or large frag-
ments of cell wall obtained from mechanically
disrupted cells are relatively ineffective (6, 15).
That is, intervals of 5 to 20 weeks may elapse
before any joint inflammation is apparent, and
the incidence of disease is low. More active
preparations are obtained by further fragmenta-
tion of the cell wall by limited enzymatic diges-
tion with muralytic enzymes or by mechanical
degradation by sonication (6, 18). This report
relates the arthropathogenic activity of PG-APS
to the particle size of the fragments obtained by
sonic degradation.
MATERIALS AND METHODS
Bacterial ceil culture. Group A, type 3, strain D-58
streptococci were grown in 15-liter batches of Todd-
Hewitt broth (BBL Microbiology Systems, Cockeys-
ville, Md.) in a Virtis fermentor (The VirTis Co.,
1003
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Gardiner, N.Y.) with continuous stirring at 37°C, and
the pH was maintained at 7.00 to 7.03 by the automatic
addition of 5 N NaOH. The 15 liters of broth was
inoculated with 500 ml of an 18-h culture. The initial
pH was 7.6, and when this reached 7.0, additional
glucose was added continuously in proportion to the
NaOH consumed. The final concentration of addition-
al glucose added was 3.0%o. The growth was monitored
by the periodic measurement of optical density, and by
this criterion, the early stationary phase was reached
at 7 h. At this time, the cells were collected in a
Pellicon filtration unit (Millipore Corp., Bedford,
Mass.). The concentrated cells were washed in the
filtration unit with 8 liters of sterile phosphate-buffered
saline (PBS), pH 7.2. The cells were concentrated to 1
liter and collected by centrifugation at 10,000 x g for
30 min.
Cell wall preparations. The washed cells were sus-
pended in approximately 100 ml of PBS (pH 7.2) so
that a 1/100 dilution gave a reading of 350 in a Klett-
Summerson colorimeter with a green (no. 54) filter.
Thirty milliliters of the cell suspension plus 1 drop of
tributyl phosphate were added to 30 g of no. 11 glass
beads, and the cells were disrupted in a Braun MSK
cell homogenizer (Bronwill Scientific Inc., Rochester,
N.Y.). Shaking for 3 to 4 min with flowing CO2 as a
cooling agent was sufficient to disrupt over 95% of the
cells. Intact cells were removed by centrifugation at
2,000 x g for 30 min, and the cell walls were collected
by centrifugation at 10,000 x g for 30 min (8,500 rpm,
Sorvall GSA rotor). The pellet was resuspended in
PBS (pH 7.2) and washed three times in PBS. The
pellet was thoroughly dispersed at each washing by
sonication for 15 s with a Branson model 350 Sonifier
(Branson Sonic Power Co., Danbury, Conn.). The cell
walls were further purified by treatment with RNase
(0.025 mg/mg of cell wall) for 4 h at 37°C with constant
shaking. They were washed once with PBS and treated
with trypsin (0.025 mg/mg) for 4 h at 37°C, washed
again, suspended in 0.1 M phosphate buffer (pH 7.0)
containing 0.001 M cysteine and 0.001 M EDTA, and
treated with papain (0.020 mg/mg) for 4 h at 37°C. The
cell walls were washed twice more in PBS, once in
water, resuspended in water, dialyzed against water,
and lyophilized. The dried walls were next suspended
in a 2:1 dilution of chloroform-methanol (40 mg/ml)
and extracted at room temperature for 2 h by stirring.
This extraction was repeated two more times. The cell
walls were washed once with water, dialyzed against
water, and lyophilized. All enzyme preparations were
filtered through a Millipore 0.45-,um filter before use.
After each sedimentation, the resuspended pellet was
dispersed by sonication for 15 s to ensure thorough
washing. The cell wall preparations were analyzed for
sugars and amino sugars by gas-liquid chromatography
and for amino acids by amino acid analyzer as de-
scribed previously (8). By these analyses the final
product was composed of components characteristic
of the PG-APS. The cell wall preparations treated only
with RNase and trypsin still contained some glucose,
which suggested contamination with lipoteichoic acid
or glycosyl glycerides of the cytoplasmic membrane.
Treatment with papain and extraction with chloro-
form-methanol removed all detectable glucose.
Preparation of fragments of purified cell wall (PG-
APS) by sonication. The lyophilized purified cell walls
were resuspended in PBS, pH 7.2 (20 mg/ml), and
subjected to sonic vibration for 70 min in a Branson
Sonifier by using a 3/4-in. (ca 1.9-cm) probe in a sealed
40-ml stainless-steel cup which was cooled with a
water jacket with flowing water at 4°C. The Sonifier
was stopped every 20 min for a 5-min period to allow
additional cooling. As the final step in the standard
preparation of PG-APS fragments for animal injection,
the sonicated suspension was filtered through a Milli-
pore 0.45-,um filter. This step removed any intact
bacteria and, most importantly, provided a criterion
for the maximum size of PG-APS fragments injected.
Between 10 and 20% of the PG-APS was removed by
filtration.
Resolution of fragments of PG-APS by sucrose gradi-
ent centrifugation. After sonication, the undegraded,
large pieces of PG-APS were removed by centrifuga-
tion at 10,000 x g for 30 min in a Sorvall SS-34 rotor.
This sedimentation removed 6 to 7% of the PG-APS.
Three milliliters of the supernatant (55 mg) was placed
on 32 ml of a 10 to 60% gradient of sucrose in PBS, pH
7.2, and centrifuged in a TV-850 vertical rotor (Sor-
vall) at 50,000 rpm (200,000 x g) at 4°C for periods of
0.5, 1, 2, and 5 h. Fractions were collected by pumping
70%6 sucrose into the bottom of the tube, and the eluate
was monitored by optical density at 254 nm. Since
there is negligible absorbance of this wavelength by
cell wall components, the optical density readings
reflect turbidity and not relative concentration. The
pooled fractions were dialyzed against several changes
of water at 4°C until the dialysate contained no sucrose
and lyophilized. Sixty-five percent of the sample was
recovered in the three major fractions. The specific
gravity of the sucrose gradients was measured with a
Zeiss refractometer.
Separation of fragments of PG-APS by differential
centrifugation. After sonication for 70 min, the suspen-
sion was centrifuged at 1,000 x g for 30 min in a
Sorvall SS-34 rotor to remove the largest particles (in
experiment 3 the suspension was centrifuged at 3,000
x g). The supernatant was centrifuged at 10,000 x g
for 30 min (SS-34 rotor). The pellet from 10,000 x g
was resuspended in PBS, pH 7.2, and labeled 10p30.
The supernatant from 10,000 x g was centrifuged at
100,000 x g for 60 min in a T-865 rotor in a Sorvall
OTD-2 ultracentrifuge. This supernatant from 100,000
x g was centrifuged again at 100,000 x g, and the final
supernatant was labeled 100s60. The pellets from
100,000 x g were resuspended in PBS, pH 7.2, for a
30-s sonication and labeled 100p60. Before analyses,
this suspension was centrifuged at 10,000 x g to
remove large aggregates. On the basis of rhamnose
determinations, 22% of the recovered fragments were
in the 10p fraction, 53% were in the 100p fraction, and
25% were in the 100s fraction. Before being injected
into animals, each preparation was sonicated for 2 min
to disperse the fragments.
PG. PG was isolated from purified cell walls of
strain D-58 group A Streptococcus by five successive
extractions with formamide at 170°C for 1 h. After the
final extraction, the insoluble residue was washed
once in water, dialyzed against water for 48 h, and
lyophilized. The details of this procedure were de-
scribed by Krause and McCarty (12). This preparation
contained 0.5% rhamnose. To prepare for injection,
100 mg was suspended in 20 ml of PBS and subjected
to sonication for 2 min in a Branson sonicator with a
20-ml chamber at a power setting of 8. This yielded a
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stable suspension with an optical density at 550 nm of
0.315. The 2-min sonication was based upon previous
experience with the biological properties ofPG (1, 10).
Another preparation was derived in the same way
from cell walls of strain K43 group A variant Strepto-
coccus. By gas-liquid chromatography analysis this
preparation had a composition of 0.9o rhamnose,
13.3% muramic acid, and 14.5% glucosamine. This
preparation, suspended in PBS as described above,
was sonicated with the Branson sonicator at a power
setting of 5. Samples were obtained before sonication
and at intervals of 18, 30, 60, and 150 s of sonication.
Each of these samples was injected i.p. into groups of
six rats in doses of 3.0, 1.0, and 0.3 mg per 100-g rat to
test for arthropathic activity.
Physical and chemical measurements ofPG-APS frag-
ments. The procedure and equipment used for light
scattering measurements and calculations of molecular
weight are described by Carr et al. (3). The refractive
index increment (dn/dc) was determined for each
fraction by the method of Carr et al (3): 100s = 0.139,
lOOp = 0.160, and 10p = 0.167. Reducing sugars were
determined by the method of Thompson and Shock-
man (20), and free amino groups were measured by
dinitrophenylation as described by Ghuysen et al. (9).
Gel Sltration of PG-APS fragments. Bio-Gel A-150
and A-50 agarose columns were prepared according to
the manufacturer's specifications (Bio-Rad Labora-
tories, Richmond, Calif.). Gels were prepared with 0.1
M phosphate buffer, pH 7.2, or 0.1 M ammonium
bicarbonate, pH 7.8. Filtration was done at 4°C at a
flow rate of 10 ml/h in columns (100 by 1.5 cm) with a
void volume of 51 ml. One milliliter of sample (10.0
mg) was added to the column, and fractions were
collected in 2.0-ml volumes in an LKB fraction collec-
tor.
Scoring of joint disease. The scoring of severity of
joint lesions by clinical assessment and by radiological
methods has been described (2, 4).
Animals. Outbred female Sprague-Dawley rats
weighing approximately 100 g were obtained from
Zivic-Miller, Allison Park, Pa.
RESULTS
Particle size of PG-APS fragments obtained by
sonication. The decrease in the average molecu-
lar weight of the PG-APS polymers with increas-
ing time of sonication was measured by light
scattering (Fig. 1). Under the conditions of soni-
cation employed, the molecular weight after 70
min was approximately 500 x 106. This repre-
sents the average size of the largest particles in
this heterogeneous mixture, since smaller parti-
cles contribute relatively little to this measure-
ment.
The change in particle size with sonication is a
reflection of the breaking of bonds in the cross-
linking peptide and in the glycan backbone of the
PG. These changes, measured by the increase in
free amino groups and reducing sugars (Fig. 2),
reached a plateau at about 70 min of sonication
under the conditions employed.
Resolution of PG-APS fragments. The hetero-









FIG. 1. Effect of sonication at different time peri-
ods upon particle size of purified group A Streptococ-
cus cell wall fragments (PG-APS), measured by light
scattering.
sonication was analyzed by sucrose gradient
centrifugation. Instead of a continuous spectrum
of particle sizes, the sonicated PG-APS resolved
into four populations (Fig. 3). Each peak moved
through the gradient between 0.5 and 5 h, which
indicates that the separation was by velocity
sedimentation rather than by equilibrium.
The PG-APS fragments derived by sonication
were also separated by differential centrifuga-
tion in PBS into three populations, labeled
100s60 (smallest), 100p60 (intermediate), and
10p30 (largest). When these isolated fractions of
different particle size were placed on sucrose
gradients, they sedimented through the gradient
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FIG. 2. Effect of sonication for different time peri-
ods on peptide cross-linking of PG-APS fragments as
measured by the increase in terminal amino acids and
effect on average length of glycan polymers as mea-
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FIG. 3. Heterogeneity of the particle size of PG-APS fragments resolved by velocity sedimentation in a
sucrose gradient. The PG-APS suspension was sonicated for 70 min and placed on a 10 to 60%o gradient. Density
increases with tube number. OD254 nm, Optical density at 254 nm.
The size distribution of the PG-APS fragments
separated by differential centrifugation was fur-
ther characterized by filtration on Bio-Gel A-150
(Fig. 5). Most of the lOOp fragments of PG-APS
were excluded on this gel, indicating a molecular
weight in excess of 150 x 106. Most of the lOOs
fragments were retained on the gel to give an
estimated size range of 4 x 106 to 150 x 106
daltons, with the most prominent population
estimated to be 4 x 106 to 6 x 106 daltons. When
examined by light scattering, the molecular
weight of the 100s60 fraction was calculated to
be 5.3 x 106, in close agreement with gel filtra-
tion. The light scattering value for the 100p60
fraction was 50 x 106 daltons, one-third the
value of the gel filtration estimate. The chemical
analysis of these fractions is shown in Table 1.
The free amino group concentration was 700
nM/mg for 1OOs60 and 480 nM/mg for the 100p60
fraction. The concentration of reducing groups,
such as glucose, was 11.5 ,ug/mg for WNWs60 and
9.4 ,ug/mg for the 100p60 fraction.
Relationship of particle size of PG-APS frag-
ments to arthropathogenicity. To determine
which fragment size was most effective in pro-
ducing experimental arthritis, three groups of
rats were injected i.p. with equivalent doses
(based upon rhamnose) of each PG-APS fraction
suspended in PBS. The results of one experi-
ment are illustrated in Fig. 6, and a summary of
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FIG. 4. Velocity sedimentation of three fractions
ofPG-APS obtained by differential centrifugation. The
PG-APS suspension was centrifuged for 2 h on a 10 to
60%o sucrose gradient.
three experiments is recorded in Table 2. The
number of rats in each group was limited by the
relatively low yield of the lOp and 100s fractions
compared with the lOOp fraction and by the
toxicity of the lOp fraction. In experiments 1 and
2, three of eight rats injected with the lOp
fraction died within 24 h.
In each of the experiments, the smallest frag-
ments (100s) produced the most severe acute
inflammation, but relatively less of the late,
recurrent, chronic joint disease. In contrast, the
intermediate-sized fragments (lOOp) produced
moderate acute inflammation, but the most se-
vere chronic, degenerative disease. In experi-
ments 1 and 3, the maximum chronic score
produced by the lOOp fraction was significantly
different (P c 0.05) from that produced by lOOs.
In experiment 1, the acute inflammation pro-
duced by 100s was significantly different from
that produced by lOOp. In experiment 3, each
fraction was tested at three concentrations. The
greater capacity of the 100s fraction to produce
acute joint inflammation compared with the lOOp
and lOp fractions was most evident with the
lower doses (P - 0.001). None of the fractions
produced persistent joint lesions with the lower
doses.
The largest fragments (lOp) produced negligi-
ble acute inflammation, and the joints appeared
negative by clinical inspection over the first 5 to
9 weeks after injection. Arthritis did become
apparent in some rats by 40 days in experiment
1, by 68 days in experiment 2, and by 41 days in
experiment 3. The lOp fraction in experiment 3
differed from the other lOp preparations in that
after resuspension in PBS, it was centrifuged at
3,000 x g for 30 min to remove the largest PG-
APS particles. Since these particles were the
least effective in inducing inflammation, their
removal left a more arthropathic preparation per
microgram of rhamnose injected.
The relative severity of the chronic, erosive
synovitis and bone destruction occurring in the
late stages of disease was confirmed by the
radiographic scores measured at the termination
of the experiments (Table 2).
Arthropathic properties of isolated PG. In the
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FIG. 5. Size distribution on Bio-Gel A-150 of PG-
APS fragments in the whole suspension of sonicated
PG-APS and in the 100p and 100s fractions separated
by differential centrifugation.
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TABLE 1. Composition of cell wall (PG-APS)
fractions
Cell wall PG-APS fractions (%)C
Componenta (%)b 10p30 lOOp60 100s60
Rhamnose 24.9 18.8 25.2 23.4
Glucose 0 0 0 0
Glucosamine 14.0 9.8 11.9 11.3
Muramic acid 5.1 3.4 4.9 3.8
Lysine NDd 5.0 5.2 5.2
Glutamic acid ND 5.7 6.1 6.8
Alanine ND 12.9 16.4 14.1
a Other amino acids, neutral sugars, and amino
sugars which were detected total less than 2% of the
lyophilized dry weight.
b Percentage of lyophilized dry weight.
c Fractions derived by differential centrifugation
from cell wall preparation treated with ribonuclease,
trypsin, and papain and extracted with chloroform-
methanol. Percentage of lyophiized dry weight.
d ND, Not determined.
7.5 mg of PG per rat from group A cell walls
suspended in PBS. Three of the rats died be-
tween 6 and 18 h, indicating that this was an
excessive dose for assessment of arthropathic
activity. Four of the surviving seven rats devel-
oped moderate acute inflammation in the joints
of the ankles and feet, consisting of erythema
and edema, which reached a peak at 3 days after
injection and rapidly subsided. The average joint
score at day 3 was 1.6 (out of a possible score of
16), and all rats were negative by clinical criteria
10 days postinjection. There was no evidence of
any recurrence of joint inflammation over a
period of 2 months. All rats were X-rayed at 43
days postinjection, and no radiographic evi-
dence of arthritis was detected.
The question of the arthropathic capacity of
PG, as opposed to PG-APS, is important for
pursuing the identification of the minimal effec-
tive structure. Therefore, further experiments
were done to determine whether PG derived
from another strain of Streptococcus and tested
in different doses and fragment sizes might be
more effective as an arthropathic agent. PG
isolated from strain K-43 group A variant strep-
tococci was sonicated and injected as described
in Materials and Methods. None of the rats
injected with the lower doses of 1.0 or 0.3 mg
developed any detectable joint inflammation.
Moderate acute inflammation of the ankles and
feet developed in the rats injected with 3.0 mg of
PG samples which were not sonicated (average
score, 2.3; 6 of 6 positive) or were sonicated for
only 18 s (average score, 2.8; 3 of 6 positive).
These responses reached a peak 3 days after
injection and rapidly subsided. Samples of PG
sonicated for 30 s or longer induced only a slight,
transient erythema in the feet over the first 48 h
in 50% of the rats. Recurrent, destructive,
chronic joint inflammation was not detectable by
clinical or radiographic assessment in any rats
over an observation period of 6 weeks after a
single i.p. injection of an aqueous suspension of
any of these preparations of PG.
DISCUSSION
The covalently bound complex of PG-APS
polymers is the etiological agent of experimental
arthritis induced by the systemic injection of
bacterial cell wall fragments in aqueous suspen-
sion (4a, 16). The progressive destruction of
joints is associated with the localization and
persistence of PG-APS in joint tissue (6, 7). The
outstanding features of this cell wall structure
are the toxicity and capacity to invoke dysfunc-
tion of the immune system, combined with
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DAY AFTER CELL WALL INJECTION
FIG. 6. Effect of particle size of PG-APS fragments isolated from group A streptococcal cell walls upon acute
and chronic joint diseases. All rats were injected i.p. with PG-APS fragments (30 ,ug of rhamnose per g of body
weight. O (large fragments), 5 rats; A (intermediate fragments), 12 rats; 0 (small fragments), 6 rats. Mean joint
score + standard error of the mean. Total of four legs; maximum score is 16. The level of significance between
the three groups was calculated for each day that scores were recorded. For clarity, the standard error of the
mean is only shown at 5-day intervals. Fraction 100s60 is significantly greater than 100p60 or 10p30 at days 2
through 18 and significantly less than fraction 100p from days 38 to 92 (P < 0.05).
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TABLE 2. Summary of the effect of particle size and dose of PG-APS fragments on acute and chronic joint
disease
Radiographic
Acute joint lesions Chronic joint lesions assessment
Expt Fraction Dosea No. No.
Scoreb PC positive/ Score"b PC positive/ Scoref Day
totald total'
1 lOOs 30 8.9 ± 0.5 0.0001 6/6 2.7 ± 0.7 NS8 5/6 1.2 ± 0.7 97
loop 30 2.0 ± 0.4 0.02 12/12 7.8 ± 1.5 NS 12/12 5.3 ± 2.2 97
lop 30 0.45 ± 0.3 2/5 5.6 ± 1.9 5/5 4.1 ± 2.7 97
2 lOOs 30 10.25 ± 1.3 10/10 7.8 ± 2.1 NS 7/10 3.0 ± 1.0 97
loop 30 8.25 ± 1.2 10/10 8.2 ± 1.8 0.05 10/10 5.0 ± 1.5 97
lop 30 0 0/5 2.6 ± 1.8 1/5 2.1 ± 2.0 97
3 lOOs 30 11.2 ± 0.4 8/8 5.2 ± 1.2 0.025 7/8 1.6 ± 0.4 62
10 4.25 ± 0.6 0.00001 8/8 0 0/8 NDh
3 0.56 ± 0.2 4/8 0 0/8 ND
loop 30 9.6 ± 0.8 0.00002 8/8 9.3 ± 1.8 0.002 7/8 3.6 ± 1.0 62
10 0.59 ± 0.2 0.04 4/8 0 0/8 ND
3 0 0/8 0 0/8 ND
lop 30 4.8 ± 0.8 8/8 1.8 ± 1.0 4/8 0.13 ± 0.1 62
10 0.12 ± 0.09 1/8 0 0/8 ND
3 0 0/8 0 0/8 ND
a Micrograms of rhamnose per gram of body weight, injected i.p. Each experiment was done with separate
batches of cell wall.
b Mean ± standard error of maximum joint scores recorded for acute inflammation (day 3 to 7 after cell wall
injection) or for chronic joint disease (day 19 to termination) by clinical evaluation.
c Level of significance compared with 10p fraction.
d Number of rats with clinically apparent joint inflammation/total number of rats injected.
' Number of rats with clinically evident recurrence of joint disease/total number of rats injected.
f Mean score of hind joints ± standard error of the mean at indicated day of termination.
8 NS, Not significant.
h ND, Not determined.
resistance to biodegradation (1, 17, 19). Al-
though the toxic properties of this complex are
associated with the PG moiety (1, 10, 11), as
shown in this report, a single injection of the
isolated PG in aqueous suspension cannot, by
itself, induce chronic erosive arthritis. This is
consistent with studies of other models in which
PG in aqueous suspension could induce acute
injury but not chronic inflammatory disease (1).
The modulation of toxicity by the polysaccha-
ride moiety is related to the rapid degradation of
PG by tissue enzymes in contrast to the persis-
tence of the PG-APS complex (13, 17, 19).
Since the isolated PG is not effective, we must
examine the PG-APS complex to define the
minimal structural unit of cell wall which can
induce and maintain a chronic inflammatory
process. The standard preparation of PG-APS
which is used to induce arthritis in rats is soni-
cated for 70 min, which yields a polydisperse
suspension of fiagments. This suspension was
resolved into discrete populations by velocity
sedimentation, which means that the peaks rep-
resent families of different particle size rather
than particles of different densities. Equilibrium
separation, reflecting density differences, would
have meant variable contamination offragments
with material such as membrane lipids.
The chemical analysis of the fractions separat-
ed by differential centrifugation showed relative-
ly small differences in composition, which pro-
vides further evidence that they represent three
populations of PG-APS fragments differing pri-
marily in average particle size.
The smaller fragments of PG-APS, with the
predominate species having a molecular weight
of 5.3 x 106, induced the early acute phase of
joint inflammation with relatively less severe
chronic disease. Larger fragments, with an aver-
age molecular weight of 500 x 106, induced a
minimal early phase but did induce a chronic
arthritis of late onset. Intermediate-size fiag-
ments, with a molecular weight of approximate-
ly 50 x 106 (by light scattering), induced both
acute and chronic phases of the disease. Thus,
instead of identifying a minimal unit of PG-APS
responsible for the bimodal acute and chronic
arthritis, this study demonstrates that fragments
of different size are responsible for different
phases of the clinical pattern of the experimental
joint disease.
The fragment size is a reflection of the length
VOL. 35, 1982
1010 FOX ET AL.
of glycan polymers (measured as reducing sugar)
and the extent of peptide cross-linking (mea-
sured as free amino groups). The larger number
offree peptide side chains in the lOOs fragments,
indicated by the higher concentration of free
amino groups, could be important in initiating
acute inflammation. Further definition of the
fine-structure properties of PG-APS required to
initiate and to maintain inflammation of the
joints is being pursued with muralytic and endo-
peptidase enzymes (C. Chetty and J. H.
Schwab, manuscript in preparation). Another
effect of size could be on transport and elimina-
tion. In support of this explanation, quantitative
measurement of PG-APS in tissues of rats dem-
onstrates that the different patterns of arthro-
pathogenesis, induced with fragments of differ-
ent size, correlate with differences in tissue
distribution and the rate of elimination (R. A.
Eisenberg, A. Fox, S. K. Anderle, R. R. Brown,
and J. H. Schwab, manuscript in preparation).
The practical significance of these observations
is that to reproduce this experimental model of
arthritis the distribution of particle sizes within a
preparation of PG-APS fragments is very impor-
tant. Thus, if a disproportionate amount of the
suspension consists of large fragments, joint
disease will not appear until several weeks after
injection, and the incidence may be low. Similar
results were obtained in other experimental
models in which the size of cell wall fragments
was an important determinant of disease (14, 15,
18).
The observations reported here are consistent
with the concept that the extent of degradation
of bacterial cells by the host may be an impor-
tant factor determining the arthropathogenicity
of the residual bacterial cell wall debris. We
hypothesize that some individuals are more sus-
ceptible because less effective degradation of
bacterial cells results in the accumulation of
sufficient quantities of toxic persistent debris,
with the consequent development of chronic
inflammation.
ACKNOWLEDGMENTS
This investigation was supported by Public Health Service
grant AM25733 from the National Institute of Arthritis, Diabe-
tes, and Digestive and Kidney Diseases, National Institutes of
Health, and A.F. was the recipient of a fellowship from the
Arthritis Foundation.
The amino acid analyses were done by David Klapper, and
Roy Hantgan assisted in determination of molecular weight by
light scattering.
LITERATURE CITED
1. Abdulla, E. M., and J. H. Schwab. 1966. Biological
properties of streptococcal cell wall particles. III. Der-
monecrotic reaction to cell wall mucopeptides. J. Bacte-
riol. 91:374-383.
2. Anderbe, S. K., J. J. Greenblatt, W. J. Cromartie, R. L.
Clark, and J. H. Schwab. 1979. Modulation of the suscep-
tibility of inbred and outbred rats to arthritis induced by
cell walls of group A streptococci. Infect. Immun. 25:484-
490.
3. Carr, M. E., Jr., L. L. Shen, and J. Herman. 1977. Mass-
length ratio of fibrin fibers from gel permeation and light
scattering. Biopolymers 16:1-15.
4. Clark, R. L., J. T. Cuttlno, Jr., S. K. Anderle, W. J.
Cromartie, and J. H. Schwab. 1979. Radiologic analysis of
arthritis in rats after systemic injection of streptococcal
cell walls. Arthritis Rheum. 22:25-35.
4a.Cromartie, W. J. 1981. Arthropathic properties of pepti-
doglycan-polysaccharide complexes of microbial origin,
p. 24-38. In H. Deicker and L. C. Schultz (ed.), Arthri-
tis-models and mechanisms. Springer-Verlag, New
York.
5. Cromartle, W. J., S. K. Anderle, J. H. Schwab, and F. G.
DaUldorf. 1979. Experimental arthritis, carditis and pinni-
tis induced by systemic injection of group A streptococcal
cell walls into guinea pigs. VII, p. 50-52. In M. T. Parker
(ed.), International symposium on streptococci and strep-
tococcal diseases. Reedbooks, Surray, England.
6. Cromartle, W. J., J. G. Craddock, J. H. Schwab, S. K.
Anderbe, and C.-H. Yang. 1977. Arthritis in rats after
systemic injection of streptococcal cells or cell walls. J.
Exp. Med. 146:1585-1602.
7. Dalldorf, F. G., W. J. Cromartle, S. K. Anderle, R. L.
Clark, and J. H. Schwab. 1980. Relation of experimental
arthritis to the distribution of streptococcal cell wall
fragments. Am. J. Pathol. 100:383-402.
8. Fox, A., J. H. Schwab, and T. Cochran. 1980. Detection of
muramic acid in mammalian tissues by gas liquid chroma-
tography-mass spectrometry. Infect. Immun. 29:526-531.
9. Ghuysen, J. M., D. J. Tipper, and J. L. Stromnlnger. 1966.
Enzymes that degrade bacterial cell walls. Methods Enzy-
mol. 8:685-689.
10. Greenblatt, J., R. J. Boackle, and J. H. Schwab. 1978.
Activation of the alternate complement pathway by pepti-
doglycan from streptococcal cell wall. Infect. Immun.
19:296-303.
11. Heymer, B., and E. T. Rietachel. 1977. Biological proper-
ties of peptidoglycans, p. 344-349. In D. Schlessinger
(ed.), Microbiology-1977. American Society for Micro-
biology, Washington, D.C.
12. Krauae, R., and M. McCarty. 1961. Studies on the chemi-
cal structure of streptococcal cell walls. I. Identification
of a mucopeptide in the cell walls of groups A and A-
variant streptococci. J. Exp. Med. 114:127-140.
13. Ohanian, S. H., and J. H. Schwab. 1967. Persistence of
group A streptococcal cell walls related to chronic inflam-
mation of rabbit dermal connective tissue. J. Exp. Med.
125:1137-1148.
14. Ohanian, S. H., J. H. Schwab, and W. J. Cromarde. 1969.
Relation of rheumatic-like cardiac lesions of the mouse to
localization of group A streptococcal cell walls. J. Exp.
Med. 129:37-49.
15. Roberson, B. S., J. H. Schwab, and W. J. Cromartie. 1960.
Relation of particle size of C polysaccharide complexes of
group A streptococci to toxic effects on connective tissue.
J. Exp. Med. 112:751-764.
16. Schwab, J. H. 1970. Significance of bacterial components
in the pathogenesis of connective tissue disease. Proc.
Int. Congr. Pharmacol. 4:226-232.
17. Schwab, J. H., and R. R. Brown. 1968. Modification of
antigenic structure in vivo: quantitative studies on the
processing of streptococcal cell wall antigens in mice. J.
Immunol. 101:930-938.
18. Schwab, J. H., H. Gooder, and W. R. Maxted. 1962.
Further studies on toxic C polysaccharide complexes of
the beta-hemolytic streptococci. Br. J. Exp. Pathol.
43:181-188.
19. Schwab, J. H., and S. H. Ohanlan. 1967. Degradation of
streptococcal cell wall antigens in vivo. J. Bacteriol.
94:1346-1352.
20. Thompson, J. S., and G. D. Shockman. 1968. A modifica-
tion of the Park and Johnson reducing sugar determination
suitable for the assay of insoluble materials: its application
to bacterial cell walls. Anal. Biochem. 22:260-268.
INFECT. IMMUN.
